Vaxxas
Vaxxas develops needle-free vaccine delivery technology to improve vaccine performance. The Brisbane-based biotech company has raised $162M and employs 130 people.
The growth story
Vaxxas grew from 74 to 130 employees between 2021 and 2026, raising $162M along the way, most recently a Series D in August 2025.
About
Vaxxas creates a novel vaccine delivery system that eliminates needles while enhancing effectiveness. Their technology aims to improve both existing vaccines and next-generation formulations, targeting pharmaceutical companies and public health organizations.
The company has secured $162M in funding, including from major backers like the Bill & Melinda Gates Foundation and Australian government agencies. With 130 employees, Vaxxas operates in Australia's growing biotech hub of Brisbane.
Founders and leadership
Engineering is Vaxxas' largest function with 16 employees. The company has a median tenure of 2 years, suggesting moderate turnover in its Brisbane-based workforce.
The Vaxxas org chart
David Peacock (Chief Executive Officer) leads 33 mapped leaders with 4 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 26 (-4% YoY), Operations 23 (-15% YoY), Quality Assurance 21 (-5% YoY), Business Development 11 (+83% YoY), Information Technology 11 (-8% YoY), Program and Project Management 6 (-14% YoY).
Talent flow
Vaxxas recruits heavily from The University of Queensland, which accounts for 21% of hires. Other key talent sources include medical device companies Ellume and Cochlear. Alumni frequently move to other Australian biotech firms and academic institutions.
Most common previous employers of Vaxxas staff: The University of Queensland (21), Ellume (15), Cochlear (7), AcuraBio (6), Cook Medical (5), QUT (Queensland University of Technology) (5). Former Vaxxas employees most often moved to The University of Queensland (6), Southern RNA 🧬 (4), AdvanCell (3), Thermo Fisher Scientific (3), Cook Medical (3), OneVentures (2).
Alumni worth knowing
The Vaxxas mafia
Four Vaxxas alumni have founded companies, including WearOptimo (29 staff) and Southern RNA (27 staff), showing entrepreneurial activity in Australia's biotech sector.
4Mark Kendall, was Founder, Chief Technology Officer, Director, Advisory Board Chair until 2015Garry Heaney, was Production Manager, Clinical Operations until 2022Fanny Blaudez, was Project Manager until 2025Yvonne W-P Woo, PhD, was Senior Operational Excellence Coordinator until 2025Web traffic
Traffic mix: 36% direct, 47% search, 7% social, 2% paid.
What this company is made of
Most common skills at Vaxxas: Good Manufacturing Practice (GMP) (36), Project Management (34), Communication (30), Leadership (30), Research Skills (29), Microsoft Office (27), Cell Culture (26), Management (25).
Where the team actually sits
Vaxxas people are concentrated in Queensland, Australia (51), Greater Brisbane Area (31), Australia (12), Greater Adelaide Area (1).
Search footprint
Vaxxas attracts about 111 organic search visits a month, traffic worth roughly $0K a month if bought through ads. It gained 12 ranking keywords and lost 10 in the last period.
What employees say
- Compensation
- 3.20 / 5
- Career opportunities
- 2.60 / 5
- Senior management
- 2.70 / 5
- Work-life balance
- 2.90 / 5
Frequently asked
Vaxxas has 130 employees as of September 2026.
Vaxxas has raised $162M in total, most recently a Series D round in August 2025.
David Peacock (Chief Executive Officer) sits at the top of Vaxxas's reporting structure, with 4 direct reports.
The most common previous employers of current Vaxxas staff are The University of Queensland (21 people), Ellume (15 people), Cochlear (7 people).
Former Vaxxas employees most often move to The University of Queensland (6), Southern RNA 🧬 (4), AdvanCell (3).
At least 4 companies have a founder who previously worked at Vaxxas, including WearOptimo, Southern RNA 🧬, EXONOVA Biotech.
Vaxxas attracts about 111 organic search visits a month, worth roughly $0K a month in equivalent ad spend.
The most common skills among Vaxxas staff are Good Manufacturing Practice (GMP), Project Management, Communication, Leadership, Research Skills.
Vaxxas staff are concentrated in Queensland, Australia (51), Greater Brisbane Area (31), Australia (12).
Vaxxas has about 26 people in Research, down 4% over the past year, as of September 2026.
Vaxxas has about 23 people in Operations, down 15% over the past year, as of September 2026.
Computed from 102 current and 115 former Vaxxas profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.